Company: CDT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010405
Chunk: 1

Company: CDT Equity Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
741 
  
    Operating lease liability, non-current portion 
     78  
     107 
  
    Derivative warrant liability 
     8  
     138 
  
    Total liabilities 
     4,634  
     10,986 

    Commitments and contingencies (see Note 15) 
     -  
     - 

    Stockholders’ equity (deficit) 

    Common stock, par value $0.0001; 250,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively, 9,512,058 shares and 1,384,801 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 
     19  
     14 
  
    Preferred stock, par value $0.0001; 1,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; nil shares issued and outstanding at March 31, 2025 and December 31, 2024 
     -  
     - 
  
    Additional paid-in capital 
     36,569  
     21,880 
  
    Accumulated deficit 
     (34,247) 
     (29,101)
  
    Accumulated other comprehensive income 
     346  
     414 
  
    Total stockholders’ equity (deficit) 
     2,687  
     (6,793)
  
    Total liabilities and stockholders’ equity (deficit) 
    $7,321  
    $4,193 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

1

CONDUIT
PHARMACEUTICALS INC.

CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in
thousands, except share and per share amounts)

    2025  
    2024 

    Three Months ended March 31, 

    2025  
    2024 
  
    Operating expenses: 

    Research and development expenses 
    $1,309  
    $128 
  
    General and administrative expenses 
     2,700  
     2,827 
  
    Total operating expenses 
     4,